Back to top
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Bio-Techne Corp (TECH) - $25 value - yours FREE >>
ANI Pharmaceuticals, Inc. (ANIP) - $25 value - yours FREE >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bio-Techne Corp (TECH) - $25 value - yours FREE >>
ANI Pharmaceuticals, Inc. (ANIP) - $25 value - yours FREE >>
Image: Bigstock
Bio-Techne (TECH) Set to Acquire Space Import-Export
Bio-Techne Corporation (TECH - Free Report) , a global developer, manufacturer and seller of clinical diagnostic products, announced plans to acquire Space Import-Export, an Italy-based distribution company in the Life Sciences space, for an undisclosed sum.
Space Import-Export is a leading distributor of life science research products like reagents, antibodies, proteins, Elisa kits and vitro diagnostic products. The company provides its highly advanced services to customers, especially in the fields of Biomedical Research and Diagnostics.
Post acquisition, Bio-Techne will be able to utilize Space Import-Export’s extensive business network in Italy. The company also aims to establish a direct link with customers in the local markets.
This acquisition is expected to enhance Bio-Techne’s presence and visibility in greater Europe by making its products highly exclusive in the market. Bio-Techne intends to meet the demand of its increasing clientele through the utilization of Space Import-Export’s best-quality reagents and instrument solutions.
In the global scenario, data from Markets and Markets reveal that the molecular diagnostics market is estimated to grow at a CAGR of 9.3% to $9,333.8 million by 2020. Notably, the reagent sector of the molecular diagnostic market has accounted for the largest share of market growth in 2015. We believe that this buyout can be highly accretive for the joint companies if such trends continue in the days ahead.
Notably, Bio-Techne boosted its M&A pipeline with the acquisition of Zephyrus Biosciences on May 21. We believe Bio-Techne would strengthen its position across geographies through these takeovers and also leverage its high-end resolutions in the emerging markets.
Key Peers
ANI Pharmaceuticals Inc (ANIP - Free Report) , CytRx Corporation and Fibrocell Science Inc are top-performing stocks in the broader medical sector.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>